by
Ravi Chakra Turaga;
Lu Yin;
Jenny J Yang;
Hsiauwei Lee;
Ivaylo Ivanov;
Chunli Yan;
Hua Yang;
Hans Grossniklaus;
Siming Wang;
Cheng Ma;
Li Sun;
Zhi-Ren Liu
Integrin αν β3 expression is altered in various diseases and has been proposed as a drug target. Here we use a rational design approach to develop a therapeutic protein, which we call ProAgio, that binds to integrin αν β3 outside the classical ligand-binding site. We show ProAgio induces apoptosis of integrin αν β3 -expressing cells by recruiting and activating caspase 8 to the cytoplasmic domain of integrin αν β3. ProAgio also has anti-angiogenic activity and strongly inhibits growth of tumour xenografts, but does not affect the established vasculature. Toxicity analyses demonstrate that ProAgio is not toxic to mice. Our study reports a new integrin-targeting agent with a unique mechanism of action, and provides a template for the development of integrin-targeting therapeutics.